<DOC>
	<DOCNO>NCT00396565</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety Extended Release Osmotic Controlled-Release Oral Delivery System ( OROS ) Paliperidone compare placebo patient Schizophrenia . Olanzapine use reference drug study .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness Safety ER OROS Paliperidone Patients With Schizophrenia</brief_title>
	<detailed_description>This multicenter , double blind ( neither patient physician know whether drug placebo take , dosage ) , randomize ( patient assign different treatment base chance ) , placebo- active-controlled , parallel-group study . Patients randomize 1 3 treatment group receive oral dosage Extended Release ( ER ) Osmotic Controlled-Release Oral Delivery System ( OROS ) paliperidone 6 mg , olanzapine 10 mg , placebo . They receive two capsule Paliperidone ER 3 mg , placebo Olanzapine 5 mg daily breakfast 6 week . The study include screen period , follow double-blind treatment 6 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients give consent write participate study Patients diagnose schizophrenia accord diagnostic criterion DSMIV ( Diagnostic Statistical Manual Mental Disorders , 295.30 , 295.10 , 295.20 , 295.90 , 295.60 ) Patients acute symptom schizophrenia Both inpatient outpatient acceptable A DSMIV ( Diagnostic Statistical Manual Mental Disorders ) mental disease diagnosis schizophrenia A DSMIV diagnosis substancerelated disorder ( except nicotine dependence caffeine dependence ) within 180 day screen test Total PANSS ( Positive Negative Syndrome System ) score screen test &lt; 70 &gt; 120 Patients treat three type antipsychotic within 28 day screen test Parkinson 's disease ( except druginduced extra pyramidal symptom ) Patients complication past history cerebrovascular accident Patients complication past history diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>JNS007ER</keyword>
	<keyword>Positive Negative Syndrome Scale ( PANSS )</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Extended Release Osmotic Controlled-Release Oral Delivery System ( OROS ) paliperidone</keyword>
</DOC>